Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma
Source: Oncology Nurse Advisor, March 2017
Rechallenge with dabrafenib plus trametinib possesses antitumor activity in patients with advanced BRAF V600-mutant melanoma who had previously progressed on BRAF inhibitor therapy, a study published in The Lancet Oncology has shown.1
Patients with BRAF V600 mutation-positive melanoma derive benefit from the combination of dabrafenib and trametinib, a BRAF inhibitor and MEK inhibitor, respectively; however, most patients develop resistance to these agents and ultimately disease progression.
Preclinical studies and case studies have suggested that acquired resistance to BRAF inhibition can be reversed. Therefore, researchers sought to evaluate the antitumor activity of rechallenge with dabrafenib and trametinib in a phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT02296996).